Dr. Nina J. Karlin, MD

Dr. Karlin practices at Mayo Clinic Ambulatory Surgery Center - Scottsdale in Scottsdale, Arizona.

Dr. Karlin's NPI, 1679661490, was assigned on October 10, 2006. Dr. Karlin graduated from Geisel School of Medicine at Dartmouth in 1996. Dr. Karlin holds Arizona license 26177.

Dr. Karlin's primary practice is Mayo Clinic Ambulatory Surgery Center - Scottsdale, at 13400 East Shea Boulevard, Scottsdale, AZ 85259. The practice phone is (480) 342-4201.

Dr. Karlin's primary practice is Mayo Clinic Ambulatory Surgery Center - Scottsdale in Scottsdale, Arizona. Dr. Karlin is also affiliated with Mayo Clinic Hospital - Phoenix. The medical group on file is Mayo Clinic Arizona. Dr. Karlin's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Karlin practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Karlin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Karlin's licenses on file in 2 states: Arizona and California.

Dmand AI lists breast cancer, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Karlin treats.

CMS data shows 53,477 Medicare services from Dr. Karlin across 48 procedure codes in 2024, for 710 Medicare patients. Medicare paid $1,373,638 for them. Every service was in an office.

CMS counts 710 Medicare patients who saw Dr. Karlin in 2024. The largest group is 65 to 74, with 354 patients. 71% of them have high cholesterol, and 69% have high blood pressure. 2% are also on Medicaid. Their average risk score is 2.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Karlin's median patient age at 70, with 66% women.

In 2024, Dr. Karlin wrote 395 Medicare Part D claims for 75 patients. 83% of them were for generic drugs. CMS names the drug for 315 of them, across 8 drugs with 11 or more claims each, at $462,585 in total drug cost. In 2023, CMS named 202 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Karlin for performance year 2024, reported as part of a group. Dr. Karlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Karlin as offering telehealth.

Dmand AI links 44 papers to Dr. Karlin, published from 2010 to 2021. 2020 was the busiest year, with 7. The most frequent topics are Indazoles, Pyrimidines and Sulfonamides. Dr. Karlin has published most often in Future Sci OA. Dr. Karlin's most frequent co-authors are Curtiss B. Cook, MD, Robert Smallridge, MD and Keith C. Bible, MD, PhD.

Dmand AI links Dr. Karlin to 3 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Medullary, Thyroid Cancer, Papillary and Carcinoma, Neuroendocrine. Eli Lilly and Company sponsors the most, 2.

CMS Open Payments shows 4 general payments to Dr. Karlin from 4 drug and device companies from 2016 to 2021. Food and beverage make up the largest share, 95% of the total. Clovis Oncology, Inc. paid the most, $83.

Dr. Karlin graduated from Geisel School of Medicine at Dartmouth in 1996.

Dr. Karlin is in network with 4 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross and Blue Shield of Kansas City. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.